| 550 | 3 | 44 |
| 下载次数 | 被引频次 | 阅读次数 |
噬菌体疗法作为耐药细菌感染的新型治疗策略备受瞩目，当前研究重点多集中于噬菌体疗法的临床疗效观察，对治疗过程中产生的某些免疫问题缺乏深入探讨。噬菌体作为外源物质，其某些成分会激活哺乳动物的固有免疫，亦会激活适应性免疫诱导机体产生中和抗体而影响治疗效果，给噬菌体疗法的推广带来挑战。本综述就噬菌体疗法的类型及其引起的不同免疫反应进行探讨，进一步阐明治疗过程中噬菌体与免疫系统相互作用、免疫系统对噬菌体治疗效果的影响及应对策略，以期为噬菌体疗法的临床应用提供参考。
Abstract：Phage therapy has attracted significant attention as an innovative strategy for combating antibiotic-resistant bacterial infections. Current research predominantly emphasizes the clinical efficacy of phage therapy, with limited in-depth investigation into immune-related issues arising during treatment. As exogenous agents, certain components of phages can activate the mammalian innate immune system and stimulate adaptive immunity, resulting in the production of neutralizing antibodies that may compromise therapeutic efficacy. These challenges hinder the broader implementation of phage therapy. This review examines the various types of phage therapy and the immune responses they elicit, elucidates the interactions between phages and the immune system, and analyzes how the immune system influences the effectiveness of phage therapy. Furthermore, it outlines strategies to mitigate these challenges, providing valuable insights for the clinical application of phage therapy.
[1] Bava R, Castagna F, Lupia C, et al. Antimicrobial resistance in livestock:a serious threat to public health[J]. Antibiotics(Basel), 2024, 13(6):551. DOI:10. 3390/antibiotics13060551.
[2] Baral B. Phages against killer superbugs:an enticing strategy against antibiotics-resistant pathogens[J].Front Pharmacol, 2023, 14:1036051. DOI:10. 3389/fphar. 2023. 1036051.
[3] Davies J, Davies D. Origins and evolution of antibiotic resistance[J]. Microbiol Mol Biol Rev, 2010, 74(3):417-433. DOI:10. 1128/MMBR. 00016-10.
[4] Collaborators AR. Global burden of bacterial antimicrobial resistance in 2019:a systematic analysis[J]. Lancet, 2022, 399(10325):629-655. DOI:10. 1016/S0140-6736(21)02724-0.
[5]熊利洋，胡秀玲，魏云林.耐药菌非抗生素疗法研究进展[J].中国生物工程杂志，2023, 43(1):50-58. DOI:10. 13523/j. cb. 2207050.
[6] Sahu R, Singh AK, Kumar A, et al. Bacteriophages concept and applications:a review on phage therapy[J].Curr Pharm Biotechnol, 2023, 24(10):1245-1264.DOI:10. 2174/1389201024666221104142457.
[7] Nazarov PA. MDR pumps as crossroads of resistance:antibiotics and bacteriophages[J]. Antibiotics(Basel),2022, 11(6):734. DOI:10. 3390/antibiotics11060734.
[8] Jault P, Leclerc T, Jennes S, et al. Efficacy and tolerability of a cocktail of bacteriophages to treat burn wounds infected by Pseudomonas aeruginosa(PhagoBurn):a randomised, controlled, double-blind phase 1/2 trial[J]. Lancet Infect Dis, 2019, 19(1):35-45. DOI:10. 1016/S1473-3099(18)30482-1.
[9] Nang SC, Lin YW, Petrovic Fabijan A, et al.Pharmacokinetics/pharmacodynamics of phage therapy:a major hurdle to clinical translation[J]. Clin Microbiol Infect, 2023, 29(6):702-709. DOI:10. 1016/j.cmi. 2023. 01. 021.
[10]Chung KM, Nang SC, Tang SS. The safety of bacteriophages in treatment of diseases caused by multidrug-resistant bacteria[J]. Pharmaceuticals(Basel), 2023, 16(10):1347. DOI:10. 3390/ph16101347.
[11]Berkson JD, Wate CE, Allen GB, et al. Phage-specific immunity impairs efficacy of bacteriophage targeting Vancomycin Resistant Enterococcus in a murine model[J]. Nat Commun, 2024, 15(1):2993. DOI:10. 1038/s41467-024-47192-w.
[12]Kaur S, Harjai K, Chhibber S. Bacteriophage-aided intracellular killing of engulfed methicillin-resistant Staphylococcus aureus(MRSA)by murine macrophages[J]. Appl Microbiol Biotechnol, 2014, 98(10):4653-4661. DOI:10. 1007/s00253-014-5643-5.
[13]Miernikiewicz P, D?browska K. Endocytosis of bacteriophages[J]. Curr Opin Virol, 2022, 52:229-235. DOI:10. 1016/j. coviro. 2021. 12. 009.
[14]Ghafouri E, Fadaie M, Amirkhani Z, et al. Evaluation of humoral and cellular immune responses against Vibrio cholerae using oral immunization by multi-epitope-phagebased vaccine[J]. Int Immunopharmacol, 2024, 134:112160. DOI:10. 1016/j. intimp. 2024. 112160.
[15]Titécat M, Rousseaux C, Dubuquoy C, et al. Safety and efficacy of an AIEC-targeted bacteriophage cocktail in a mice colitis model[J]. J Crohns Colitis, 2022, 16(10):1617-1627. DOI:10. 1093/ecco-jcc/jjac064.
[16]Liu K, Wang C, Zhou X, et al. Bacteriophage therapy for drug-resistant Staphylococcus aureus infections[J].Front Cell Infect Microbiol, 2024, 14:1336821. DOI:10. 3389/fcimb. 2024. 1336821.
[17]Ramirez-Sanchez C, Gonzales F, Buckley M, et al.Successful treatment of Staphylococcus aureus prosthetic joint infection with bacteriophage therapy[J]. Viruses,2021, 13(6):1182. DOI:10. 3390/v13061182.
[18]K?hler T, Luscher A, Falconnet L, et al. Personalized aerosolised bacteriophage treatment of a chronic lung infection due to multidrug-resistant Pseudomonas aeruginosa[J]. Nat Commun, 2023, 14(1):3629.DOI:10. 1038/s41467-023-39370-z.
[19]Anyaegbunam NJ, Anekpo CC, Anyaegbunam ZKG,et al. The resurgence of phage-based therapy in the era of increasing antibiotic resistance:From research progress to challenges and prospects[J]. Microbiol Res,2022, 264:127155.DOI:10. 1016/j.micres. 2022. 127155.
[20]Nikolich MP, Filippov AA. Bacteriophage therapy:developments and directions[J]. Antibiotics(Basel),2020, 9(3):135. DOI:10. 3390/antibiotics9030135.
[21]Costa P, Pereira C, Romalde JL, et al. A game of resistance:War between bacteria and phages and how phage cocktails can be the solution[J]. Virology, 2024,599:110209. DOI:10. 1016/j. virol. 2024. 110209.
[22]Jokar J, Saleh RO, Rahimian N, et al. Antibacterial effects of single phage and phage cocktail against multidrug-resistant Klebsiella pneumoniae isolated from diabetic foot ulcer[J]. Virus Genes, 2023, 59(4):635-642. DOI:10. 1007/s11262-023-02004-z.
[23]Mani I. Phage and phage cocktails formulations[J].Prog Mol Biol Transl Sci, 2023, 200:159-169. DOI:10. 1016/bs. pmbts. 2023. 04. 007.
[24]Ashworth EA, Wright RCT, Shears RK, et al.Exploiting lung adaptation and phage steering to clear pan-resistant Pseudomonas aeruginosa infections in vivo[J]. Nat Commun, 2024, 15(1):1547. DOI:10. 1038/s41467-024-45785-z.
[25]Van Nieuwenhuyse B, Galant C, Brichard B, et al. A case of in situ phage therapy against Staphylococcus aureus in a bone allograft polymicrobial biofilm infection:outcomes and phage-antibiotic interactions[J]. Viruses,2021, 13(10):1898. DOI:10. 3390/v13101898.
[26]Necel A, Bloch S, Topka-Bielecka G, et al.Synergistic effects of bacteriophage vB_Eco4-M7 and selected antibiotics on the biofilm formed by shiga toxinproducing Escherichia coli[J]. Antibiotics(Basel),2022, 11(6):712. DOI:10. 3390/antibiotics11060712.
[27]Shlezinger M, Coppenhagen-Glazer S, Gelman D, et al. Eradication of vancomycin-resistant enterococci by combining phage and vancomycin[J]. Viruses, 2019, 11(10):954. DOI:10. 3390/v11100954.
[28]Kortright KE, Chan BK, Koff JL, et al. Phage therapy:a renewed approach to combat antibioticresistant bacteria[J]. Cell Host Microbe, 2019, 25(2):219-232. DOI:10. 1016/j. chom. 2019. 01. 014.
[29]Hong Q, Chang RYK, Assafiri O, et al. Optimizing in vitro phage-ciprofloxacin combination formulation for respiratory therapy of multi-drug resistant Pseudomonas aeruginosa infections[J]. Int J Pharm, 2024, 652:123853. DOI:10. 1016/j. ijpharm. 2024. 123853.
[30]Song J, Liu Z, Zhang Q, et al. Phage engineering for targeted multidrug-resistant Escherichia coli[J]. Int J Mol Sci, 2023, 24(3):2459. DOI:10. 3390/ijms24032459.
[31]Raza A, Fatima P, Yasmeen B, et al. From resistance to remedy:the role of clustered regularly interspaced short palindromic repeats system in combating antimicrobial resistance-a review[J]. Naunyn Schmiedebergs Arch Pharmacol, 2024. DOI:10. 1007/s00210-024-03509-6.
[32]Gencay YE, Jasinskyt?D, Robert C, et al. Engineered phage with antibacterial CRISPR-Cas selectively reduce E. coli burden in mice[J]. Nat Biotechnol, 2024, 42(2):265-274. DOI:10. 1038/s41587-023-01759-y.
[33]Hatoum-Aslan A. Phage genetic engineering using CRISPR-Cas systems[J]. Viruses, 2018, 10(6):335. DOI:10. 3390/v10060335.
[34]Li T, Li S, Kang Y, et al. Harnessing the evolving CRISPR/Cas9 for precision oncology[J]. J Transl Med, 2024, 22(1):749. DOI:10. 1186/s12967-024-05570-4.
[35]Ji F, Tian G, Shang D, et al. Antimicrobial peptide2K4L disrupts the membrane of multidrug-resistant Acinetobacter baumannii and protects mice against sepsis[J]. Front Microbiol, 2023, 14:1258469. DOI:10. 3389/fmicb. 2023. 1258469.
[36]Bahrami M, Serati Shirazi P, Moradi F, et al. How nanomaterials act against bacterial structures? a narrative review focusing on nanoparticle molecular mechanisms[J]. Microb Pathog, 2024, 196:107002.DOI:10. 1016/j. micpath. 2024. 107002.
[37]Ilomuanya MO, Enwuru NV, Adenokun E, et al.Chitosan-based microparticle encapsulated Acinetobacter baumannii phage cocktail in hydrogel matrix for the management of multidrug resistant chronic wound infection[J]. Turk J Pharm Sci, 2022, 19(2):187-195. DOI:10. 4274/tjps. galenos. 2021. 72547.
[38]Szymczak M, Pankowski JA, Kwiatek A, et al. An effective antibiofilm strategy based on bacteriophages armed with silver nanoparticles[J]. Sci Rep, 2024, 14(1):9088. DOI:10. 1038/s41598-024-59866-y.
[39]Chen L, Wu MY, Chen SL, et al. The guardian of vision:intelligent bacteriophage-based eyedrops for clinical multidrug-resistant ocular surface infections[J].Adv Mater, 2024, 36(38):e2407268. DOI:10. 1002/adma. 202407268.
[40]Hagh Ranjbar H, Hosseini-Abari A, Ghasemi SM, et al. Antibacterial activity of Epsilon-poly-l-lysine produced by Stenotrophomonas maltophilia HS4 and Paenibacillus polymyxa HS5, alone and in combination with bacteriophages[J]. Microbiology(Reading),2023, 169(7):001363. DOI:10. 1099/mic. 0. 001363.
[41]Stachurska X, Mizielińska M, Ordon M, et al. The use of plant extracts and bacteriophages as an alternative therapy approach in combatting bacterial infections:the study of lytic phages and Stevia rebaudiana[J]. J Vet Res, 2023, 67(4):545-557. DOI:10. 2478/jvetres-2023-0059.
[42]Pires DP, Costa AR, Pinto G, et al. Current challenges and future opportunities of phage therapy[J]. FEMS Microbiol Rev, 2020, 44(6):684-700. DOI:10. 1093/femsre/fuaa017.
[43]Podlacha M, Gaffke L, Grabowski?，et al.Bacteriophage DNA induces an interrupted immune response during phage therapy in a chicken model[J].Nat Commun, 2024, 15(1):2274. DOI:10. 1038/s41467-024-46555-7.
[44]Soehnlein O, Lindbom L. Phagocyte partnership during the onset and resolution of inflammation[J]. Nat Rev Immunol, 2010, 10(6):427-439. DOI:10. 1038/nri2779.
[45]Gogokhia L, Buhrke K, Bell R, et al. Expansion of bacteriophages is linked to aggravated intestinal inflammation and colitis[J]. Cell Host Microbe, 2019,25(2):285-299. e8. DOI:10. 1016/j.chom. 2019. 01. 008.
[46]Roach DR, No?l B, Chollet-Martin S, et al. Human neutrophil response to Pseudomonas bacteriophage PAK_P1, a therapeutic candidate[J]. Viruses, 2023,15(8):1726. DOI:10. 3390/v15081726.
[47]Ghasemi H, Ghazanfari T, Yaraee R, et al. Roles of IL-8 in ocular inflammations:a review[J]. Ocul Immunol Inflamm, 2011, 19(6):401-412. DOI:10. 3109/09273948. 2011. 618902.
[48]Sweere JM, Van Belleghem JD, Ishak H, et al.Bacteriophage trigger antiviral immunity and prevent clearance of bacterial infection[J]. Science, 2019, 363(6434):eaat9691. DOI:10. 1126/science. aat9691.
[49]Pouw RB, Ricklin D. Tipping the balance:intricate roles of the complement system in disease and therapy[J]. Semin Immunopathol, 2021, 43(6):757-771.DOI:10. 1007/s00281-021-00892-7.
[50]Abd El-Aziz AM, Elgaml A, Ali YM. Bacteriophage therapy increases complement-mediated Lysis of bacteria and enhances bacterial clearance after acute lung infection with multidrug-resistant Pseudomonas aeruginosa[J]. J Infect Dis, 2019, 219(9):1439-1447. DOI:10. 1093/infdis/jiy678.
[51]Egido JE, Dekker SO, Toner-Bartelds C, et al.Human complement inhibits myophages against Pseudomonas aeruginosa[J]. Viruses, 2023, 15(11):2211. DOI:10. 3390/v15112211.
[52]Chechushkov A, Kozlova Y, Baykov I, et al. Influence of caudovirales phages on humoral immunity in mice[J].Viruses, 2021, 13(7):1241. DOI:10. 3390/v13071241.
[53]Dedrick RM, Smith BE, Cristinziano M, et al. Phage therapy of Mycobacterium infections:compassionate use of phages in 20 patients with drug-resistant mycobacterial disease[J]. Clin Infect Dis, 2023, 76(1):103-112. DOI:10. 1093/cid/ciac453.
[54]Dan JM, Lehman SM, Al-Kolla R, et al. Development of host immune response to bacteriophage in a lung transplant recipient on adjunctive phage therapy for a multidrug-resistant pneumonia[J]. J Infect Dis, 2023,227(3):311-316. DOI:10. 1093/infdis/jiac368.
[55]Gembara K, D?browska K. Phage-specific antibodies[J]. Curr Opin Biotechnol, 2021, 68:186-192. DOI:10. 1016/j. copbio. 2020. 11. 011.
[56]Brzozowska E, Lipiński T, Korzeniowska-Kowal A, et al. Detection and level evaluation of antibodies specific to environmental bacteriophage I11mO19 and related coliphages in non-immunized human sera[J]. Antibiotics(Basel), 2023, 12(3):586. DOI:10. 3390/antibiotics12030586.
[57]舒飞鸿.不同给药途径在噬菌体治疗中的研究进展[J].重庆医学，2022, 51(21):3743-3749. DOI:10. 3969/j. issn. 1671-8348. 2022. 21. 028.
[58]Archana A, Patel PS, Kumar R, et al. Neutralizing antibody response against subcutaneously injected bacteriophages in rabbit model[J]. Virusdisease, 2021,32(1):38-45. DOI:10. 1007/s13337-021-00673-8.
[59]Sarker SA, Berger B, Deng Y, et al. Oral application of Escherichia coli bacteriophage:safety tests in healthy and diarrheal children from Bangladesh[J]. Environ Microbiol, 2017, 19(1):237-250. DOI:10. 1111/1462-2920. 13574.
[60]Ka?mierczak Z, Majewska J, Miernikiewicz P, et al.Immune response to therapeutic staphylococcal bacteriophages in mammals:kinetics of induction,immunogenic structural proteins, natural and induced antibodies[J]. Front Immunol, 2021, 12:639570.DOI:10. 3389/fimmu. 2021. 639570.
[61]?aczek M，?usiak-Szelachowska M, Jończyk-Matysiak E, et al. Antibody production in response to staphylococcal MS-1 phage cocktail in patients undergoing phage therapy[J]. Front Microbiol, 2016,7:1681. DOI:10. 3389/fmicb. 2016. 01681.
[62]Majewska J, Ka?mierczak Z, Lahutta K, et al.Induction of phage-specific antibodies by two therapeutic staphylococcal bacteriophages administered per os[J].Front Immunol, 2019, 10:2607. DOI:10. 3389/fimmu. 2019. 02607.
[63]D?browska K, Miernikiewicz P, Piotrowicz A, et al.Immunogenicity studies of proteins forming the T4phage head surface[J]. J Virol, 2014, 88(21):12551-12557. DOI:10. 1128/JVI. 02043-14.
[64]Scheithauer TPM, Wortelboer K, Winkelmeijer M, et al. Bacteriophages from treatment-na?ve type 2 diabetes individuals drive an inflammatory response in human cocultures of dendritic cells and T cells[J]. Gut Microbes,2024, 16(1):2380747. DOI:10. 1080/19490976. 2024. 2380747.
[65]Li R, Rouse M, Pace BT, et al. Host CD3+T-cells can significantly modulate phage treatment effects on bacterial bioburden in mouse models[J]. Front Microbiol, 2023, 14:1240176. DOI:10. 3389/fmicb. 2023. 1240176.
[66]Van Belleghem JD, Clement F, Merabishvili M, et al.Pro-and anti-inflammatory responses of peripheral blood mononuclear cells induced by Staphylococcus aureus and Pseudomonas aeruginosa phages[J]. Sci Rep, 2017, 7(1):8004. DOI:10. 1038/s41598-017-08336-9.
[67]Tkhilaishvili T, Merabishvili M, Pirnay JP, et al.Successful case of adjunctive intravenous bacteriophage therapy to treat left ventricular assist device infection[J]. J Infect, 2021, 83(3):e1-e3. DOI:10. 1016/j.jinf. 2021. 05. 027.
[68]Duplessis C, Biswas B, Hanisch B, et al. Refractory Pseudomonas bacteremia in a 2-year-old sterilized by bacteriophage therapy[J]. J Pediatric Infect Dis Soc,2018, 7(3):253-256. DOI:10. 1093/jpids/pix056.
[69]Doub JB, Ng VY, Johnson AJ, et al. Salvage bacteriophage therapy for a chronic MRSA prosthetic joint infection[J]. Antibiotics(Basel), 2020, 9(5):241. DOI:10. 3390/antibiotics9050241.
[70]Ujmajuridze A, Chanishvili N, Goderdzishvili M, et al.Adapted bacteriophages for treating urinary tract infections[J]. Front Microbiol, 2018, 9:1832. DOI:10. 3389/fmicb. 2018. 01832.
[71]Kim KP, Cha JD, Jang EH, et al. PEGylation of bacteriophages increases blood circulation time and reduces T-helper type 1 immune response[J]. Microb Biotechnol, 2008, 1(3):247-257. DOI:10. 1111/j. 1751-7915. 2008. 00028. x.
[72]Hodyra-Stefaniak K, Lahutta K, Majewska J, et al.Bacteriophages engineered to display foreign peptides may become short-circulating phages[J]. Microb Biotechnol, 2019, 12(4):730-741. DOI:10. 1111/1751-7915. 13414.
[73]袁文源，林焱，朱伟云.一种实验室去除噬菌体制剂内毒素方法的建立[J].病毒学报，2024, 40(4):823-829. DOI:10. 13242/j. cnki. bingduxuebao. 004492.
[74]Suh GA, Lodise TP, Tamma PD, et al.Considerations for the use of phage therapy in clinical practice[J]. Antimicrob Agents Chemother, 2022, 66(3):e0207121. DOI:10. 1128/AAC. 02071-21.
[75]Onallah H, Hazan R, Nir-Paz R, et al. Compassionate use of bacteriophages for failed persistent infections during the first 5 years of the Israeli phage therapy center[J]. Open Forum Infect Dis, 2023, 10(5):ofad221.DOI:10. 1093/ofid/ofad221.
[76]Yang Q, Le S, Zhu T, et al. Regulations of phage therapy across the world[J]. Front Microbiol, 2023,14:1250848. DOI:10. 3389/fmicb. 2023. 1250848.
[77]Onallah H, Yerushalmy O, Braunstein R, et al.Protocol for phage matching, treatment, and monitoring for compassionate bacteriophage use in non-resolving infections[J]. STAR Protoc, 2024, 5(2):102949.DOI:10. 1016/j. xpro. 2024. 102949.
基本信息:
DOI：10.13242/j.cnki.bingduxuebao.004673
中图分类号:R392
引用信息:
[1]卢瑞辞,王瑞琳,刘心伟,等.噬菌体疗法及其对免疫系统影响的研究进展[J].病毒学报,2025,41(04):1087-1096.DOI:10.13242/j.cnki.bingduxuebao.004673.
基金信息:
河南省科技攻关（项目号：242102310148）,题目：高毒力耐碳青霉烯类肺炎克雷伯菌噬菌体鸡尾酒的研发及应用研究; 河南省自然科学基金（项目号：242300420437）,题目：噬菌体裂解酶LysPa22调控c-di-GMP抑制铜绿假单胞菌生物膜形成的作用研究; 河南中医药大学2023年度研究生科研创新计划（项目号：2023KYCX050）,题目：耐碳青霉烯类鲍曼不动杆菌噬菌的分离鉴定及其宿主菌抗性机制的初步研究~~